Clinical Reviews in Allergy & Immunology

, Volume 44, Issue 1, pp 98–108 | Cite as

The Clinical and Diagnostic Significance of Anti-myosin Autoantibodies in Cardiac Disease

Article

Abstract

Autoimmunity is influenced by genetic, immune, hormonal, and environmental factors. Viral infections may trigger autoimmunity. It has been established that autoimmunity may be a contributing factor in the pathogenesis of heart disease. Anti-heart autoantibodies have been identified in the sera of patients with heart diseases, as well as in low titers in certain healthy individuals. Nevertheless, the role of humoral immunity in the development of autoimmune heart disease has not been fully established. Anti-myosin autoantibodies appear in several heart diseases such as myocarditis, dilated cardiomyopathy, Chagas' heart disease, Kawasaki disease, rheumatic fever, and ischemic myocardium. The pathogenic role of anti-myosin autoantibodies in heart disease is not fully understood. Moreover, little is known concerning the clinical implications of anti-myosin autoantibodies in heart disease and its prognostic significance. Anti-cardiac myosin autoantibodies were found to cross-react with the β-adrenergic receptor. Studies have reported the effective use of the anti-myosin directed immune-modulating approach in animals with heart disease, although no specific anti-myosin autoantibody therapeutic approach has been attempted in humans. Herein, we review the current knowledge of anti-myosin autoantibodies and the use of targeted immune-modulating therapy in different heart diseases.

Keywords

Myosin Anti-myosin autoantibodies Myocarditis Dilated cardiomyopathy Ischemic cardiomyopathy Autoimmunity 

References

  1. 1.
    Shoenfeld Y, Gilburd B, Abu-Shakra M et al (2008) The mosaic of autoimmunity: genetic factors involved in autoimmune diseases—2008. Isr Med Assoc J 10:3–7PubMedGoogle Scholar
  2. 2.
    Shoenfeld Y, Zandman-Goddard G, Stojanovich L et al (2008) The mosaic of autoimmunity: hormonal and environmental factors involved in autoimmune diseases—2008. Isr Med Assoc J 10:8–12PubMedGoogle Scholar
  3. 3.
    Nussinovitch U, Shoenfeld Y (2009) Autoimmunity and heart diseases: pathogenesis and diagnostic criteria. Arch Immunol Ther Exp (Warsz) 57:95–104CrossRefGoogle Scholar
  4. 4.
    Matsuura E, Kobayashi K, Koike T, Shoenfeld Y (2002) Autoantibody-mediated atherosclerosis. Autoimmun Rev 1:348–353PubMedCrossRefGoogle Scholar
  5. 5.
    Sherer Y, Shoenfeld Y (2002) Atherosclerosis. Ann Rheum Dis 61:97–99PubMedCrossRefGoogle Scholar
  6. 6.
    Nussinovitch U, Shoenfeld Y (2010) Anti-troponin autoantibodies and the cardiovascular system. Heart 96:1518–1524PubMedCrossRefGoogle Scholar
  7. 7.
    Portig I, Sandmoeller A, Kreilinger S, Maisch B (2009) HLA-DQB1* polymorphism and associations with dilated cardiomyopathy, inflammatory dilated cardiomyopathy and myocarditis. Autoimmunity 42:33–40PubMedCrossRefGoogle Scholar
  8. 8.
    Liu W, Li WM, Yang SS et al (2006) Association of HLA class II DRB1, DPA1 and DPB1 polymorphism with genetic susceptibility to idiopathic dilated cardiomyopathy in Chinese Han nationality. Autoimmunity 39:461–467PubMedCrossRefGoogle Scholar
  9. 9.
    Liu W, Li WM, Sun NL (2004) Relationship between HLA-DQA1 polymorphism and genetic susceptibility to idiopathic dilated cardiomyopathy. Chin Med J (Engl) 117:1449–1452Google Scholar
  10. 10.
    Osa A, Almenar L, Palencia M, Puig N, Chirivella M, Montoro J (1999) Antigens of the major histocompatibility system in ischemic heart disease and idiopathic dilated cardiomyopathy. Clin Cardiol 22:292–296PubMedCrossRefGoogle Scholar
  11. 11.
    Hernandez-Pacheco G, Aguilar-Garcia J, Flores-Dominguez C et al (2003) MHC class II alleles in Mexican patients with rheumatic heart disease. Int J Cardiol 92:49–54PubMedCrossRefGoogle Scholar
  12. 12.
    Guilherme L, Kalil J (2010) Rheumatic fever and rheumatic heart disease: cellular mechanisms leading autoimmune reactivity and disease. J Clin Immunol 30:17–23PubMedCrossRefGoogle Scholar
  13. 13.
    Fujinami RS, von Herrath MG, Christen U, Whitton JL (2006) Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. Clin Microbiol Rev 19:80–94PubMedCrossRefGoogle Scholar
  14. 14.
    Horwitz MS, Knudsen M, Ilic A, Fine C, Sarvetnick N (2006) Transforming growth factor-beta inhibits Coxsackievirus-mediated autoimmune myocarditis. Viral Immunol 19:722–733PubMedCrossRefGoogle Scholar
  15. 15.
    Tam PE (2006) Coxsackievirus myocarditis: interplay between virus and host in the pathogenesis of heart disease. Viral Immunol 19:133–146PubMedCrossRefGoogle Scholar
  16. 16.
    Latif N, Zhang H, Archard LC, Yacoub MH, Dunn MJ (1999) Characterization of anti-heart antibodies in mice after infection with Coxsackie B3 virus. Clin Immunol 91:90–98PubMedCrossRefGoogle Scholar
  17. 17.
    Molina V, Shoenfeld Y (2005) Infection, vaccines and other environmental triggers of autoimmunity. Autoimmunity 38:235–245PubMedCrossRefGoogle Scholar
  18. 18.
    Orbach H, Shoenfeld Y (2007) Vaccination infection and autoimmunity: myth and reality VIAMR 2005-10-26-28, Beau-Rivage Palace Hotel, Lausanne, Switzerland. Autoimmun Rev 6:261–266PubMedCrossRefGoogle Scholar
  19. 19.
    Nussinovitch U, Shoenfeld Y (2009) Autoimmune mechanisms in cardiovascular diseases. Harefuah 148(173–176):210Google Scholar
  20. 20.
    Jahns R, Boivin V, Lohse MJ (2006) Beta 1-adrenergic receptor-directed autoimmunity as a cause of dilated cardiomyopathy in rats. Int J Cardiol 112:7–14PubMedCrossRefGoogle Scholar
  21. 21.
    Brucato A, Maestroni S, Cumetti D et al (2008) Recurrent pericarditis: infectious or autoimmune? Autoimmun Rev 8:44–47PubMedCrossRefGoogle Scholar
  22. 22.
    Gershwin ME (2008) The mosaic of autoimmunity. Autoimmun Rev 7:161–163PubMedCrossRefGoogle Scholar
  23. 23.
    Stojanovich L, Marisavljevich D (2008) Stress as a trigger of autoimmune disease. Autoimmun Rev 7:209–213PubMedCrossRefGoogle Scholar
  24. 24.
    Shoenfeld Y, Blank M, Abu-Shakra M et al (2008) The mosaic of autoimmunity: prediction, autoantibodies, and therapy in autoimmune diseases—2008. Isr Med Assoc J 10:13–19PubMedGoogle Scholar
  25. 25.
    Gleicher N, Barad D, Weghofer A (2007) Functional autoantibodies. A new paradigm in autoimmunity? Autoimmun Rev 7:42–45PubMedCrossRefGoogle Scholar
  26. 26.
    Fritzler MJ (2008) Challenges to the use of autoantibodies as predictors of disease onset, diagnosis and outcomes. Autoimmun Rev 7:616–620PubMedCrossRefGoogle Scholar
  27. 27.
    Shoenfeld Y, Gershwin ME, Meroni PL (2007) Autoantibodies, 2nd edn. Elsevier Science, Maryland HeightsGoogle Scholar
  28. 28.
    Jahns R, Boivin V, Schwarzbach V, Ertl G, Lohse MJ (2008) Pathological autoantibodies in cardiomyopathy. Autoimmunity 41:454–461PubMedCrossRefGoogle Scholar
  29. 29.
    Caforio AL, Brucato A, Doria A et al (2010) Anti-heart and anti-intercalated disk autoantibodies: evidence for autoimmunity in idiopathic recurrent acute pericarditis. Heart 96:779–784PubMedCrossRefGoogle Scholar
  30. 30.
    Caforio AL, Goldman JH, Baig MK et al (1997) Cardiac autoantibodies in dilated cardiomyopathy become undetectable with disease progression. Heart 77:62–67PubMedGoogle Scholar
  31. 31.
    Wehlou C, Delanghe JR (2009) Detection of antibodies in cardiac autoimmunity. Clin Chim Acta 408:114–122PubMedCrossRefGoogle Scholar
  32. 32.
    Warraich RS, Dunn MJ, Yacoub MH (1999) Subclass specificity of autoantibodies against myosin in patients with idiopathic dilated cardiomyopathy: pro-inflammatory antibodies in DCM patients. Biochem Biophys Res Commun 259:255–261PubMedCrossRefGoogle Scholar
  33. 33.
    Li Y, Heuser JS, Cunningham LC, Kosanke SD, Cunningham MW (2006) Mimicry and antibody-mediated cell signaling in autoimmune myocarditis. J Immunol 177:8234–8240PubMedGoogle Scholar
  34. 34.
    Galvin JE, Hemric ME, Kosanke SD, Factor SM, Quinn A, Cunningham MW (2002) Induction of myocarditis and valvulitis in lewis rats by different epitopes of cardiac myosin and its implications in rheumatic carditis. Am J Pathol 160:297–306PubMedCrossRefGoogle Scholar
  35. 35.
    Cunningham MW (2001) Cardiac myosin and the TH1/TH2 paradigm in autoimmune myocarditis. Am J Pathol 159:5–12PubMedCrossRefGoogle Scholar
  36. 36.
    Caforio AL, Grazzini M, Mann JM et al (1992) Identification of alpha- and beta-cardiac myosin heavy chain isoforms as major autoantigens in dilated cardiomyopathy. Circulation 85:1734–1742PubMedCrossRefGoogle Scholar
  37. 37.
    Goldman JH, Keeling PJ, Warraich RS et al (1995) Autoimmunity to alpha myosin in a subset of patients with idiopathic dilated cardiomyopathy. Br Heart J 74:598–603PubMedCrossRefGoogle Scholar
  38. 38.
    Yanase K, Smith RM, Puccetti A, Jarett L, Madaio MP (1997) Receptor-mediated cellular entry of nuclear localizing anti-DNA antibodies via myosin 1. J Clin Invest 100:25–31PubMedCrossRefGoogle Scholar
  39. 39.
    Warraich RS, Griffiths E, Falconar A et al (2006) Human cardiac myosin autoantibodies impair myocyte contractility: a cause-and-effect relationship. FASEB J 20:651–660PubMedCrossRefGoogle Scholar
  40. 40.
    Neu N, Rose NR, Beisel KW, Herskowitz A, Gurri-Glass G, Craig SW (1987) Cardiac myosin induces myocarditis in genetically predisposed mice. J Immunol 139:3630–3636PubMedGoogle Scholar
  41. 41.
    Liao L, Sindhwani R, Rojkind M, Factor S, Leinwand L, Diamond B (1995) Antibody-mediated autoimmune myocarditis depends on genetically determined target organ sensitivity. J Exp Med 181:1123–1131PubMedCrossRefGoogle Scholar
  42. 42.
    Ko YT, Hartner WC, Kale A, Torchilin VP (2009) Gene delivery into ischemic myocardium by double-targeted lipoplexes with anti-myosin antibody and TAT peptide. Gene Ther 16:52–59PubMedCrossRefGoogle Scholar
  43. 43.
    Mascaro-Blanco A, Alvarez K, Yu X et al (2008) Consequences of unlocking the cardiac myosin molecule in human myocarditis and cardiomyopathies. Autoimmunity 41:442–453PubMedCrossRefGoogle Scholar
  44. 44.
    Lauer B, Padberg K, Schultheiss HP, Strauer BE (1994) Autoantibodies against human ventricular myosin in sera of patients with acute and chronic myocarditis. J Am Coll Cardiol 23:146–153PubMedCrossRefGoogle Scholar
  45. 45.
    Cunningham MW, Meissner HC, Heuser JS, Pietra BA, Kurahara DK, Leung DY (1999) Anti-human cardiac myosin autoantibodies in Kawasaki syndrome. J Immunol 163:1060–1065PubMedGoogle Scholar
  46. 46.
    Skyllouriotis P, Skyllouriotis-Lazarou M, Natter S et al (1999) IgG subclass reactivity to human cardiac myosin in cardiomyopathy patients is indicative of a Th1-like autoimmune disease. Clin Exp Immunol 115:236–247PubMedCrossRefGoogle Scholar
  47. 47.
    Wang QQ, Wang YL, Yuan HT, Liu FQ, Jin YP, Han B (2006) Immune tolerance to cardiac myosin induced by anti-CD4 monoclonal antibody in autoimmune myocarditis rats. J Clin Immunol 26:213–221PubMedCrossRefGoogle Scholar
  48. 48.
    Neu N, Beisel KW, Traystman MD, Rose NR, Craig SW (1987) Autoantibodies specific for the cardiac myosin isoform are found in mice susceptible to Coxsackievirus B3-induced myocarditis. J Immunol 138:2488–2492PubMedGoogle Scholar
  49. 49.
    Alvarez FL, Neu N, Rose NR, Craig SW, Beisel KW (1987) Heart-specific autoantibodies induced by Coxsackievirus B3: identification of heart autoantigens. Clin Immunol Immunopathol 43:129–139PubMedCrossRefGoogle Scholar
  50. 50.
    Neu N, Craig SW, Rose NR, Alvarez F, Beisel KW (1987) Coxsackievirus induced myocarditis in mice: cardiac myosin autoantibodies do not cross-react with the virus. Clin Exp Immunol 69:566–574PubMedGoogle Scholar
  51. 51.
    Kuan AP, Zuckier L, Liao L, Factor SM, Diamond B (2000) Immunoglobulin isotype determines pathogenicity in antibody-mediated myocarditis in naive mice. Circ Res 86:281–285PubMedCrossRefGoogle Scholar
  52. 52.
    Gauntt CJ, Higdon AL, Arizpe HM et al (1993) Epitopes shared between Coxsackie virus B3 (CVB3) and normal heart tissue contribute to CVB3-induced murine myocarditis. Clin Immunol Immunopathol 68:129–134PubMedCrossRefGoogle Scholar
  53. 53.
    Beisel KW, Srinivasappa J, Prabhakar BS (1991) Identification of a putative shared epitope between Coxsackie virus B4 and alpha cardiac myosin heavy chain. Clin Exp Immunol 86:49–55PubMedCrossRefGoogle Scholar
  54. 54.
    Gauntt CJ, Arizpe HM, Higdon AL et al (1995) Molecular mimicry, anti-Coxsackie virus B3 neutralizing monoclonal antibodies, and myocarditis. J Immunol 154:2983–2995PubMedGoogle Scholar
  55. 55.
    Penninger JM, Bachmaier K (2000) Review of microbial infections and the immune response to cardiac antigens. J Infect Dis 181(Suppl 3):S498–S504PubMedCrossRefGoogle Scholar
  56. 56.
    Smith SC, Allen PM (1991) Myosin-induced acute myocarditis is a T cell-mediated disease. J Immunol 147:2141–2147PubMedGoogle Scholar
  57. 57.
    Lauer B, Schannwell M, Kuhl U, Strauer BE, Schultheiss HP (2000) Antimyosin autoantibodies are associated with deterioration of systolic and diastolic left ventricular function in patients with chronic myocarditis. J Am Coll Cardiol 35:11–18PubMedCrossRefGoogle Scholar
  58. 58.
    Caforio AL, Goldman JH, Haven AJ, Baig KM, Libera LD, McKenna WJ (1997) Circulating cardiac-specific autoantibodies as markers of autoimmunity in clinical and biopsy-proven myocarditis. The Myocarditis Treatment Trial Investigators. Eur Heart J 18:270–275PubMedCrossRefGoogle Scholar
  59. 59.
    Lappe JM, Pelfrey CM, Tang WH (2008) Recent insights into the role of autoimmunity in idiopathic dilated cardiomyopathy. J Card Fail 14:521–530PubMedCrossRefGoogle Scholar
  60. 60.
    Bromelow KV, Souberbielle B, Alavi A et al (1997) Lack of T cell response to cardiac myosin and a reduced response to PPD in patients with idiopathic dilated cardiomyopathy. J Autoimmun 10:219–227PubMedCrossRefGoogle Scholar
  61. 61.
    Nussinovitch U, Shoenfeld Y (2008) Autoimmune dilated cardiomyopathy. In: Shoenfeld Y, Cervera R, Gershwin M (eds) Diagnostic criteria in autoimmune diseases. Humana, New Jersey, pp 367–372CrossRefGoogle Scholar
  62. 62.
    Staudt Y, Mobini R, Fu M, Felix SB, Kuhn JP, Staudt A (2003) Beta1-adrenoceptor antibodies induce apoptosis in adult isolated cardiomyocytes. Eur J Pharmacol 466:1–6PubMedCrossRefGoogle Scholar
  63. 63.
    Iwai LK, Juliano MA, Juliano L, Kalil J, Cunha-Neto E (2005) T-cell molecular mimicry in Chagas disease: identification and partial structural analysis of multiple cross-reactive epitopes between Trypanosoma cruzi B13 and cardiac myosin heavy chain. J Autoimmun 24:111–117PubMedCrossRefGoogle Scholar
  64. 64.
    Ballinas-Vedugo MA, Alejandre-Aguilar R, Aranda-Fraustro A, Reyes PA, Monteon VM (2003) Anti-myosin autoantibodies are more frequent in non-Chagasic cardiomyopathy than in Chagasic cardiomyopathy patients. Int J Cardiol 92:101–102PubMedCrossRefGoogle Scholar
  65. 65.
    Talvani A, Rocha MO, Ribeiro AL, Borda E, Sterin-Borda L, Teixeira MM (2006) Levels of anti-M2 and anti-beta1 autoantibodies do not correlate with the degree of heart dysfunction in Chagas’ heart disease. Microbes Infect 8:2459–2464PubMedCrossRefGoogle Scholar
  66. 66.
    Goin JC, Leiros CP, Borda E, Sterin-Borda L (1997) Interaction of human chagasic IgG with the second extracellular loop of the human heart muscarinic acetylcholine receptor: functional and pathological implications. FASEB J 11:77–83PubMedGoogle Scholar
  67. 67.
    Leon JS, Daniels MD, Toriello KM, Wang K, Engman DM (2004) A cardiac myosin-specific autoimmune response is induced by immunization with Trypanosoma cruzi proteins. Infect Immun 72:3410–3417PubMedCrossRefGoogle Scholar
  68. 68.
    Leon JS, Godsel LM, Wang K, Engman DM (2001) Cardiac myosin autoimmunity in acute Chagas’ heart disease. Infect Immun 69:5643–5649PubMedCrossRefGoogle Scholar
  69. 69.
    Leon JS, Wang K, Engman DM (2003) Myosin autoimmunity is not essential for cardiac inflammation in acute Chagas’ disease. J Immunol 171:4271–4277PubMedGoogle Scholar
  70. 70.
    Krisher K, Cunningham MW (1985) Myosin: a link between streptococci and heart. Science 227:413–415PubMedCrossRefGoogle Scholar
  71. 71.
    Cunningham MW, McCormack JM, Fenderson PG, Ho MK, Beachey EH, Dale JB (1989) Human and murine antibodies cross-reactive with streptococcal M protein and myosin recognize the sequence GLN-LYS-SER-LYS-GLN in M protein. J Immunol 143:2677–2683PubMedGoogle Scholar
  72. 72.
    Nussinovitch U, Shoenfeld Y (2008) Intravenous immunoglobulin—indications and mechanisms in cardiovascular diseases. Autoimmun Rev 7:445–452PubMedCrossRefGoogle Scholar
  73. 73.
    Moraru M, Roth A, Keren G, George J (2006) Cellular autoimmunity to cardiac myosin in patients with a recent myocardial infarction. Int J Cardiol 107:61–66PubMedCrossRefGoogle Scholar
  74. 74.
    Pang H, Liao Y, Wang Z, Dong J, Lu Q (2000) Effect of anti-cardiac myosin antibody on prognosis of patients with acute myocardial infarction. J Tongji Med Univ 20:46–48PubMedCrossRefGoogle Scholar
  75. 75.
    Caforio AL, Goldman JH, Baig MK, Keeling PJ, Bottazzo GF, McKenna WJ (1995) Organ-specific cardiac autoantibodies in dilated cardiomyopathy—an update. Eur Heart J 16(Suppl O):68–70PubMedCrossRefGoogle Scholar
  76. 76.
    Caforio AL, Tona F, Bottaro S et al (2008) Clinical implications of anti-heart autoantibodies in myocarditis and dilated cardiomyopathy. Autoimmunity 41:35–45PubMedCrossRefGoogle Scholar
  77. 77.
    Wang Y, Afanasyeva M, Hill SL, Kaya Z, Rose NR (2000) Nasal administration of cardiac myosin suppresses autoimmune myocarditis in mice. J Am Coll Cardiol 36:1992–1999PubMedCrossRefGoogle Scholar
  78. 78.
    Wallukat G, Muller J, Hetzer R (2002) Specific removal of beta1-adrenergic autoantibodies from patients with idiopathic dilated cardiomyopathy. N Engl J Med 347:1806PubMedCrossRefGoogle Scholar
  79. 79.
    Yuan Z, Shioji K, Nimata M, Kishimoto C (2004) Cardioprotective effects of carvedilol on acute autoimmune myocarditis. Mol Cell Biochem 259:223–227PubMedCrossRefGoogle Scholar
  80. 80.
    Nagatomo Y, Yoshikawa T, Kohno T et al (2009) A pilot study on the role of autoantibody targeting the beta1-adrenergic receptor in the response to beta-blocker therapy for congestive heart failure. J Card Fail 15:224–232PubMedCrossRefGoogle Scholar
  81. 81.
    Yuan HT, Liao YH, Wang Z et al (2003) Prevention of myosin-induced autoimmune myocarditis in mice by anti-L3T4 monoclonal antibody. Can J Physiol Pharmacol 81:84–88PubMedCrossRefGoogle Scholar
  82. 82.
    Smith SC, Allen PM (1992) Neutralization of endogenous tumor necrosis factor ameliorates the severity of myosin-induced myocarditis. Circ Res 70:856–863PubMedCrossRefGoogle Scholar
  83. 83.
    Liu W, Nakamura H, Shioji K et al (2004) Thioredoxin-1 ameliorates myosin-induced autoimmune myocarditis by suppressing chemokine expressions and leukocyte chemotaxis in mice. Circulation 110:1276–1283PubMedCrossRefGoogle Scholar
  84. 84.
    Cihakova D, Barin JG, Baldeviano GC et al (2008) L.E.A.P.S. heteroconjugate is able to prevent and treat experimental autoimmune myocarditis by altering trafficking of autoaggressive cells to the heart. Int Immunopharmacol 8:624–633PubMedCrossRefGoogle Scholar
  85. 85.
    Horwitz MS, Ilic A, Fine C, Sarvetnick N (2005) Induction of antigen specific peripheral humoral tolerance to cardiac myosin does not prevent CB3-mediated autoimmune myocarditis. J Autoimmun 25:102–111PubMedCrossRefGoogle Scholar
  86. 86.
    Rose NR (2009) Myocarditis: infection versus autoimmunity. J Clin Immunol 29:730–737PubMedCrossRefGoogle Scholar
  87. 87.
    Zimmermann O, Rodewald C, Radermacher M et al (2010) Interferon beta-1b therapy in chronic viral dilated cardiomyopathy—is there a role for specific therapy? J Card Fail 16:348–356PubMedCrossRefGoogle Scholar
  88. 88.
    Maixent JM, Paganelli F, Scaglione J, Levy S (1998) Antibodies against myosin in sera of patients with idiopathic paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol 9:612–617PubMedCrossRefGoogle Scholar
  89. 89.
    Matsunaga K, Kawai T, Kato K, Tani K, Ohkubo T (1991) Antimyosin antibodies in CNS-lupus. Tohoku J Exp Med 163:211–218PubMedCrossRefGoogle Scholar
  90. 90.
    Morgun A, Shulzhenko N, Unterkircher CS et al (2004) Pre- and post-transplant anti-myosin and anti-heat shock protein antibodies and cardiac transplant outcome. J Heart Lung Transplant 23:204–209PubMedCrossRefGoogle Scholar
  91. 91.
    Ruchala M, Kosowicz J, Baumann-Antczak A, Skiba A, Zamyslowska H, Sowinski J (2007) The prevalence of autoantibodies to: myosin, troponin, tropomyosin and myoglobin in patients with circulating triiodothyronine and thyroxine autoantibodies (THAA). Neuro Endocrinol Lett 28:259–266PubMedGoogle Scholar
  92. 92.
    Bijlsma JW, Plater-Zyberk C, Mumford P, Maini RN (1990) Lack of natural antibodies in rheumatic diseases. Rheumatol Int 10:107–112PubMedCrossRefGoogle Scholar
  93. 93.
    Currie PF, Goldman JH, Caforio AL et al (1998) Cardiac autoimmunity in HIV related heart muscle disease. Heart 79:599–604PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of Internal Medicine BChaim Sheba Medical CenterTel HashomerIsrael
  2. 2.Sackler Faculty of MedicineTel Aviv UniversityTel AvivIsrael
  3. 3.Incumbent of the Laura Schwarz-Kipp Chair for Research of Autoimmune DiseasesTel-Aviv UniversityTel-AvivIsrael
  4. 4.Department of Medicine ‘B’ and Zabludowicz Center for Autoimmune DiseasesChaim Sheba Medical CenterTel HashomerIsrael

Personalised recommendations